Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Cardiovascular or arteriothrombotic adverse events (CV- or AT-AEs) are reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). The incidence and characteristics across different TKI have not been systematically analyzed. We analyzed 531 patients treated wi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Jain, Preetesh, Kantarjian, Hagop, Boddu, Prajwal C., Nogueras-González, Graciela M., Verstovsek, Srdan, Garcia-Manero, Guillermo, Borthakur, Gautam, Sasaki, Koji, Kadia, Tapan M., Sam, Princy, Ahaneku, Hycienth, O’Brien, Susan, Estrov, Zeev, Ravandi, Farhad, Jabbour, Elias, Cortes, Jorge E.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2019
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6436011/
https://ncbi.nlm.nih.gov/pubmed/30885996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018025874
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares